Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript

Bill Collier: Yes. I think what we said so far in that study is that we’ll have some initial data in the first half of next year. I think Karen also mentioned earlier on is still somewhat dependent upon recruitment rates into each of those arms. You’re right that our ultimate aim would be to combine 1709 and 101 with the nuclear side. But we’ve not yet provided any time lines for that.

Thomas Yip: Okay, understand. Thank you for taking our questions. And we’re looking forward to the [Indiscernible].

Bill Collier: Thank you.

Operator: Thank you. And this concludes the question-and-answer session. I would now like to turn it back to management for closing remarks.

Bill Collier: Okay. Well, look, thank you very much, everyone, for joining us this morning. We appreciate your continued interest in and support of Arbutus and your questions. We very much look forward to providing you updates as we progress the development of our HBV clinical stage assets over coming months. So operator, that concludes our call for this morning.

Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.